News
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin....
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials,...
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to...
From May 21-26, for the first time, the Davos Forum will feature The House of Psychedelics. Here's why that matters...
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks....
Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients....
Wesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this means for the company and...
This is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications....
Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience....
Our resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial sense....